<SEC-DOCUMENT>0001171843-26-003866.txt : 20260602
<SEC-HEADER>0001171843-26-003866.hdr.sgml : 20260602
<ACCEPTANCE-DATETIME>20260602093003
ACCESSION NUMBER:		0001171843-26-003866
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20260602
FILED AS OF DATE:		20260602
DATE AS OF CHANGE:		20260602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Legend Biotech Corp
		CENTRAL INDEX KEY:			0001801198
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39307
		FILM NUMBER:		261053884

	BUSINESS ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
		BUSINESS PHONE:		732-850-5598

	MAIL ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_060126.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>Date of Report: June 2, 2026</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39307</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Legend Biotech Corporation</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>2101 Cottontail Lane<br />Somerset, New Jersey 08873</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br />Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>&#160;</p><p>&#160;</p><!--<p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u>&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u>&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.&#160;</p>--><hr style="page-break-after: always;" noshade="noshade" /><p> <p><strong>Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026</strong></p><p>On June 2, 2026, Legend Biotech Corporation (&#8220;Legend Biotech&#8221;) announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), will be presented during a late-breaking session at the European Hematology Association (&#8220;EHA&#8221;) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden.</p><p>The press release is attached to this Form 6-K as Exhibit 99.1.</p><p>The EHA abstract #7249 is attached to this Form 6-K as Exhibit 99.2. Exhibit 99.2 to this report is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p><p>The information contained in this Form 6-K, but excluding Exhibit 99.2, is hereby incorporated herein by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-278050, 333-272222, and 333-257625) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.</p><p style="text-align: center;"><u> <font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font> </u></p><p style="text-align: center;"><font style="font-size: 10pt;">&#160;</font></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td valign="bottom"><font style="font-size: 10pt;"><strong>Exhibit</strong></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="font-size: 10pt;"><strong>Title</strong></font></td></tr><tr><td>&#160;</td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_991.htm">Press Release dated June 2, 2026</a> </font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_992.htm">99.2</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_992.htm">EHA Abstract, dated June 2, 2026</a> </font></td></tr></table><p></p><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%"><strong>&#160;&#160;&#160;&#160;Legend Biotech Corporation&#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: June 2, 2026</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%">&#160;&#160;&#160;&#160;/s/ Ying Huang&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Ying Huang, Ph.D.</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Chief Executive Officer  </td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
 <ul type="disc"><li style="margin-bottom:6pt;"><em>Promising Phase 1 data for LB2501, a potential first</em><em>&#8209;</em><em>in</em><em>&#8209;</em><em>class CD19/CD20 dual</em><em>&#8209;</em><em>targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B</em><em>&#8209;</em><em>cell malignancies</em></li><li style="margin-bottom:6pt;"><em>An ORR of 100% (6/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5/6) in patients with relapsed/ refractory NHL</em></li><li style="margin-bottom:6pt;"><em>Data demonstrate robust in vivo CAR</em>-<em>T expansion without lymphodepleting chemotherapy </em></li><li style="margin-bottom:6pt;"><em>Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS </em><em><u>&lt;</u></em><em>Grade 2<br ><br ></em></li></ul>  <p align="justify">BRIDGEWATER, N.J., June  02, 2026  (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational <em>in vivo </em>CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), will be presented during a late-breaking session at the European Hematology Association (EHA) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden.</p>  <p align="justify">&#8220;The upcoming presentation of Phase 1 LB2501 data in patients with B-cell malignancies represents an important step in advancing <em>in vivo</em> CAR-T approaches,&#8221; said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. &#8220;By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies. LB2501 is built on the TaVec&#153; platform, which is a proprietary lentiviral vector engineered to enhance T-cell specificity, transduction efficiency, and safety, while restricting transduction of non-T cells.&#8221;</p>  <p align="justify"><strong>LB2501: Promising Phase 1 Trial of </strong><strong><em>In Vivo</em></strong><strong> CAR-T Data Demonstrate High Response Rates in B-cell Malignancies</strong></p>  <p align="justify">Data from 12 patients across two dose cohorts in an ongoing Phase 1 study evaluating LB2501 in patients with R/R B-NHL provide early clinical evidence supporting the potential of an <em>in vivo</em> CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within the patient following a single intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion.</p>  <p align="justify">As of April 1, 2026, 12 patients with R/R B-NHL were treated across two dose levels (DL1 and DL2). Additional details will be presented at EHA 2026. Key findings from the abstract include:</p>  <p align="justify"><strong>Efficacy Results</strong></p>  <ul type="disc"><li style="text-align:justify;">At DL2 (median follow-up for DL2 was 2.2 months [range, 2.0 to 3.8]) <ul type="circle"><li style="text-align:justify;">Objective response rate (ORR): 100% (6/6)</li><li style="text-align:justify;">Complete response rate (CR): 83.3% (5/6)</li><li style="text-align:justify;">All responses were ongoing at data cutoff<br ><br ></li></ul> </li></ul>  <p align="justify"><strong>Pharmacokinetics </strong></p>  <ul type="disc"><li style="text-align:justify;">Dose-dependent <em>in vivo </em>CAR-T expansion observed</li><li style="text-align:justify;">CAR-T cells detected in peripheral blood for up to 116 days<br ><br ></li></ul>  <p align="justify"><strong>Safety Results</strong></p>  <ul type="disc"><li>No dose-limiting toxicities (DLTs), serious adverse events (SAEs), or deaths were observed</li><li>Infusion-related reactions occurred in 75% of patients, all of which were &#8804; Grade 2</li><li>Cytokine release syndrome (CRS) occurred in 66.7% of patients, all of which were &#8804; Grade 2</li><li>No immune effector cell-associated neurotoxicity syndrome (ICANS) was reported</li><li>Grade &#8805;3 lentiviral vector-related and CAR-T-related adverse events were limited to decreased lymphocyte count and decreased neutrophil count<br ><br ></li></ul>  <p><strong>EHA Presentation (June 11-14, 2026)</strong></p> <table style="width:100%; border-collapse:collapse !important;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; "><tr><td style="max-width:19%; width:19%; min-width:19%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; "><strong>Abstract No.</strong></td><td style="max-width:51%; width:51%; min-width:51%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; "><strong>Title</strong></td><td style="max-width:30%; width:30%; min-width:30%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; "><strong>Information</strong></td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Abstract #LB5006<br >Late-Breaking Oral Presentation</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">First-in-human trial of LB2501, an <em>in vivo</em> CD19/CD20 dual targeting CAR-T therapy, in relapsed/refractory B-Cell NHL<br ><br ></td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; "><strong>Session ID: </strong>s204<br ><strong>Date/Time:</strong> Sunday, June 14, 2026, 9:15-10:45 AM CEST<br ><strong>Location:</strong> Nobel Hall</td></tr></table> <p align="left"><br ></p>  <p align="justify"><strong>ABOUT LB2501</strong><br >LB2501 is an investigational, potential first-in-class CD19/CD20 dual-targeting <em>in vivo</em> CAR-T therapy designed to generate CAR-T cells directly within the patient following a single intravenous infusion. It is being evaluated in an ongoing Phase 1, open-label study NCT07002112) in patients with relapsed/refractory B-cell malignancies to assess safety, tolerability, and preliminary efficacy.<sup>i</sup></p>  <p align="justify"><strong>ABOUT B-CELL NON-HODGKIN LYMPHOMA</strong><br >Non-Hodgkin lymphoma (NHL) is a group of cancers that originate in lymphocytes, a type of white blood cell that plays a key role in the body&#8217;s immune system.<sup>ii</sup> B-cell lymphomas account for approximately 85% of NHL cases and arise from abnormal growth of B lymphocytes (B cells), which are responsible for producing antibodies. These malignancies include a range of subtypes that vary in aggressiveness, from slow-growing to highly aggressive disease.<sup>iii</sup></p>  <p align="justify"><strong>ABOUT&#160;LEGEND BIOTECH</strong><br >With over 3,000 employees,&#160;Legend Biotech&#160;is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever.&#160;Legend Biotech&#160;is at the forefront of the CAR-T cell therapy revolution with CARVYKTI<sup>&#174;</sup>, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson &amp; Johnson. Centered in&#160;the United States,&#160;Legend Biotech&#160;is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI&#8217;s patient access and therapeutic potential. From this platform,&#160;Legend Biotech&#160;plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.</p>  <p align="justify">Learn more at&#160;https://legendbiotech.com&#160;and follow us on&#160;X, Instagram,&#160;and&#160;LinkedIn.</p>  <p align="justify"><strong>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</strong><br ><br ><em>Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute &#8220;forward-looking statements&#8221; within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech&#8217;s strategies and objectives, the potential benefits of the proprietary TaVec platform, the Phase 1 clinical trial of LB2501 and the potential benefits of LB2501, including its potential to be first-in-class. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech&#8217;s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend Biotech&#8217;s third-party partners; uncertainties arising from challenges to Legend Biotech&#8217;s patent or other proprietary intellectual property protection, including the uncertainties involved in the&#160;U.S.&#160;litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the &#8220;Risk Factors&#8221; section of Legend Biotech&#8217;s Annual Report on Form 20-F filed with the&#160;Securities and Exchange Commission&#160;on&#160;March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release.&#160;Legend Biotech&#160;specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.</em></p>  <p><strong>INVESTOR CONTACT:</strong><br >Jessie Yeung<br >Tel: (732) 956-8271<br >investor@legendbiotech.com</p>  <p><strong>PRESS CONTACT:</strong><br >Kim Fox<br >Tel: (848) 388-8445<br >media@legendbiotech.com</p>  <p><sup>i</sup> ClinicalTrials.Gov. The CD19/&#8203;CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/&#8203;Refractory B-cell Malignancies. https://clinicaltrials.gov/study/NCT07002112. Accessed May 2026<br ><sup>ii</sup> American Cancer Society. &#8220;What Is Non-Hodgkin Lymphoma?&#8221;. Available at: https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html.Accessed May 2026.<br ><sup>iii</sup> American Cancer Society. &#8220;Types of B-cell Lymphoma.&#8221; Available at: https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/b-cell-lymphoma.html.Accessed May 2026.</p> <p></p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exh_992.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html lang="en-US"><head><title>EdgarFiling</title>
<meta content="text/html; charset=windows-1252" >
<meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head>
<body>
<p>

<p style="text-align: right; margin-top: 0; margin-bottom: 0"><b>EXHIBIT 99.2</b></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Topic: 26. Gene therapy, cellular immunotherapy and vaccination - Clinical</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b><u>EHA-7249</u></b></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>First-in-human trial of LB2501, an in vivo CD19/CD20 dual targeting CAR-T therapy, in relapsed/refractory B-Cell NHL</b></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Type: None selected</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; text-indent: -0.3pt; margin-top: 0pt; margin-bottom: 0pt"><b>Xiaoyan Qu</b><font style="font-size: 10pt"><sup>1</sup></font> Yajing Zhang<font style="font-size: 10pt"><sup>2</sup></font> Haisheng Liu<font style="font-size: 10pt"><sup>3</sup></font> Heng Mei<font style="font-size: 10pt"><sup>4</sup></font> Kaiyang Ding<font style="font-size: 10pt"><sup>5</sup></font> Jujuan Wang<font style="font-size: 10pt"><sup>1</sup></font> Sanmei Wang<font style="font-size: 10pt"><sup>1</sup></font> Haorui Shen<font style="font-size: 10pt"><sup>1</sup></font> Zhengxu Sun<font style="font-size: 10pt"><sup>1</sup></font> Shuangshuang Xing<font style="font-size: 10pt"><sup>1</sup></font> Guoai Su<font style="font-size: 10pt"><sup>2</sup></font> Zheng Li<font style="font-size: 10pt"><sup>3</sup></font> Lin Liu<font style="font-size: 10pt"><sup>4</sup></font> Ran Li<font style="font-size: 10pt"><sup>1</sup></font> Hailing Liu<font style="font-size: 10pt"><sup>1</sup></font> Ling
Zhou<font style="font-size: 10pt"><sup>6</sup></font> Yinrui Jiang<font style="font-size: 10pt"><sup>6</sup></font> Yongxin Luo<font style="font-size: 10pt"><sup>6</sup></font> Baoming Ni<font style="font-size: 10pt"><sup>7</sup></font> Dong Geng<font style="font-size: 10pt"><sup>7</sup></font> Guowei Fang<font style="font-size: 10pt"><sup>7</sup></font> Yanjie Xu<font style="font-size: 10pt"><sup>6</sup></font> Cong Feng<font style="font-size: 10pt"><sup>6</sup></font> Wenjie Wang<font style="font-size: 10pt"><sup>6</sup></font> Da Xu<font style="font-size: 10pt"><sup>6</sup></font> Zhongyuan Tu<font style="font-size: 10pt"><sup>6</sup></font> Hongchen Zheng<font style="font-size: 10pt"><sup>6</sup></font> Bing Gao<font style="font-size: 10pt"><sup>6</sup></font> Jin Liu<font style="font-size: 10pt"><sup>6</sup></font> Lei Fan<font style="font-size: 10pt"><sup>1</sup></font></p>

<p style="font-size: 10pt; text-indent: -0.3pt; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt">&#160;</font></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt"><sup>1</sup></font> The First Affiliated Hospital of Nanjing Medical University, Department of Hematology, Nanjing, China, <font style="font-size: 10pt"><sup>2</sup></font> Beijing GoBroad Boren Hospital, Gobroad Medical Institute of Hematology, Department of Myeloma and Lymphoma, Beijing, China, <font style="font-size: 10pt"><sup>3</sup></font> The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, <font style="font-size: 10pt"><sup>4</sup></font> Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Institute of Hematology, Wuhan, China, <font style="font-size: 10pt"><sup>5</sup></font> The First Affiliated Hospital of USTC Anhui Provincial Hospital, Department of Hematology, Hefei, China, <font style="font-size: 10pt"><sup>6</sup></font> Legend Biotech Co, Nanjing, China, <font style="font-size: 10pt"><sup>7</sup> </font>Legend Biotech USA Inc,
Somerset, NJ, United States of America</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>Background</b></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Ex vivo CAR-T therapies have advanced treatment for relapsed/refractory non-Hodgkin lymphoma (R/R NHL) but are limited by complex manufacturing and lymphodepletion. In vivo CAR-T offers an off-the-shelf alternative that generates CAR-T cells directly in patients without requiring lymphodepletion. While feasibility has been shown in multiple myeloma, clinical data for B-cell malignancies remain unreported. LB2501, a third-generation, replication-incompetent lentiviral vector (LVV) pseudotyped with a modified fusion glycoprotein and a CD3 binder for T-cell-specific transduction, encodes a CD19/CD20 dual targeting CAR to generate CAR-T in vivo.</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>Aims</b></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">To evaluate the safety, pharmacokinetics, and preliminary efficacy of LB2501 in R/R B-NHL.</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>Methods</b></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">This ongoing phase 1 trial (NCT07002112) enrolled patients with measurable R/R NHL who had primary refractory disease or progression after &ge;2 prior lines of therapy. A 3+3 dose-escalation design with backfilling was used across dose levels (DLs). LB2501 was administered as a single intravenous infusion without lymphodepletion.</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>Results</b></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">As of April 1, 2026, 12 patients had been dosed with LB2501 at DL1 (n=6) or DL2 (n=6). The median age was 58.5 years, median prior therapy lines was 3, and 58.3% were refractory to last line. Patients included 7 (58.3%) LBCL, 3 (25%) FL and 2 (16.7%) MCL. No DLT, SAE or fatal cases were reported. Infusion-related reactions occurred in 9 patients (75.0%); all were grade 1 or 2, resolved within a median of 2.0 days, and required no tocilizumab or glucocorticoids. Cytokine release syndrome (CRS) occurred in 66.7% patients (grade 1 in 58.3%, grade 2 in 8.3%); No neurotoxicity (ICANS) was observed. Grade&ge;3 LVV-related and CAR-T-related adverse events were limited to decreased lymphocyte count (33.3% each) and decreased neutrophil count (25.0% and 50.0%, respectively). The objective response rate (ORR) was 50% (6/12), with a complete response rate (CR) of 41.7% (5/12). At DL2, the ORR was 100% (6/6) and the CR was 83.3% (5/6).
All responses were ongoing at cut-off date (Figure 1). The median follow-up for DL2 was 2.2 months (range, 2.0 to 3.8). PK analysis via qPCR confirmed dose-dependent in vivo CAR-T cell expansion in 83% (5/6) of patients at DL1 and 100% (6/6) at DL2. At DL2, the median C<font style="font-size: 10pt">max </font>was 109,117.5 copies/&mu;g DNA (vs. 1,068.0 at DL1), with a median T<font style="font-size: 10pt">max </font>of 15.0 days. At the time of data cutoff, patients exhibited persistent PK, with CAR-T cells detectable in peripheral blood for up to 116 days. Insertion site analyses indicate in vivo transduction is highly T cell specific, polyclonal, and diverse with mostly single copy insertion per T cell. <font style="text-decoration: line-through Red">The median VCN for in vivo CAR-T was 1.05, lower than ex vivo manufactured CAR-T.</font></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>Summary/Conclusion</b></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">This study represents the initial clinical cohort of in vivo CAR-T therapy in relapsed/refractory non-Hodgkin lymphoma. LB2501, a first-in-class CD19/CD20 dual-targeting in vivo vector, introduces a novel paradigm by eliminating the need for ex vivo manufacturing and lymphodepletion. LB2501 has demonstrated a favorable safety profile and encouraging efficacy with a 100% ORR and 83.3% CR at DL2. While a longer-follow up is warranted, these data highlight the potential of LB2501 as a scalable, readily accessible &ldquo;off-the-shelf&rdquo; immunotherapy for B-cell malignancies.</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><img src="exh992_fig1.jpg" alt="" ></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Figure 1: Patient Responses to DL2</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>exh992_fig1.jpg
<TEXT>
begin 644 exh992_fig1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $% <T# 2(  A$! Q$!_\0
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MA:9_SYI^9H T,CU%&1ZBL_\ L+3/^?-/S-']A:9_SYI^9H T,CU%&1ZBL_\
ML+3/^?-/S-']A:9_SYI^9H T,CU%&1ZBL_\ L+3/^?-/S-']A:9_SYI^9H T
M,CU%&1ZBL_\ L+3/^?-/S-']A:9_SYI^9H T,CU%&1ZUG_V%IG_/FGYFD.A:
M9D?Z(GYG_&@#1R/449'J*S_["TS_ )\T_,T?V%IG_/FGYF@#0R/449'J*S_[
M"TS_ )\T_,T?V%IG_/FGYF@#0R/449'J*S_["TS_ )\T_,T?V%IG_/FGYF@#
M0R/449'J*S_["TS_ )\T_,T?V%IG_/FGYF@#0R/449'J*S_["TS_ )\T_,T?
MV%IG_/FGYF@#0R/449'J*S_["TS_ )\T_,T?V%IG_/FGYF@#0R/6C(]16<-"
MTSG_ $1.OJ?\:7^PM,_Y\T_,T :&1ZBC(]16?_86F?\ /FGYFC^PM,_Y\T_,
MT :&1ZBC(]16?_86F?\ /FGYFC^PM,_Y\T_,T :&1ZBC(]16?_86F?\ /FGY
MFC^PM,_Y\T_,T :&1ZBC(]16?_86F?\ /FGYFC^PM,_Y\T_,T :&1ZBC(]16
M?_86F?\ /FGYFC^PM,_Y\T_,T :&1ZTO7I6:="TP#_CT3\S_ (TW2[>*VN=0
MAA79&LRX7)X_=K0!J4444 ,=$D0HZAE88*D9!%5QIUBML;46=N+<G)B$2["?
MI5NB@"DFE:='(DB6%JKQ_<98E!7Z<4W6O^0'>_\ 7!OY5?JAK7_(#O?^N#?R
MH GL_P#CT@_ZY+_*K%5[/_CT@_ZY+_*K% !1110 4444 %%%% !1110 4444
M !Z4B_='TI3TI%^Z/I0 M%%% !1110 4444 %%%% !1110 4AZBEI#U% "T4
M44 %%%% !1110 4444 %%%% !1110 U>_P!33J:O?ZFG4 %%%% !1110 444
M4 %%%% !1110 UNE4[+_ )"&I?\ 75/_ $6M7&Z53LO^0AJ7_75/_1:T 7J*
M** "BBB@ JAK7_(#O?\ K@W\JSH;_4XM1S>Q,+.69XTVQEBH'W3\JY&?4UHZ
MU_R [W_K@W\J )[/_CT@_P"N2_RJQ7%ZF5;6=/C:5\FQ!2%I"D<ISR,]GQTJ
M!(;;]SY<[R<LL7FSLOG>L4G/RRCLW>@#NZ*X2.*V(A\N=Y/F98O-G9?-]8I.
M?ED'8]Z$BMOW/ESO)\Q6+S9V7S/6*3GY9!_"W?\ F =W17"1Q6V8O+G=_F98
MC+.R^8>\4G/RN.S4)%;#R@D[O\Y6+S9V7S#WADY^60?PMW_F =W17!I%;#RM
MD[L-Y6/SIV7>>\,O/RN/X6_R1(K8>7Y<[MARL?G3L-S=X9>?E?\ NMW_ )@'
M>45P:16_[KRYV.'*Q^=.PW-WAEYX;^ZW^2+%;?N_+G<XD*Q^=.PRW>&;GAO[
MK?Y(!WE%<$D=N/+VS/Q(53SIV'S=X9>>#_=?_)%BMU\O9.^!(50SSM][O#+S
MP?[K4 =Z>E(OW17S+\6?$.JZ%KME;Z/K-[;PM;EGB69@Z-O;Y7YY(]>XQ7GW
M_">^+?\ H8=2_P"_[4 ?;E%?$?\ PGOBW_H8=2_[_M1_PGOBW_H8=2_[_M0!
M]N45\1_\)[XM_P"AAU+_ +_M1_PGOBW_ *&'4O\ O^U 'VY17Q'_ ,)[XM_Z
M&'4O^_[4?\)[XM_Z&'4O^_[4 ?;E%?$?_">^+?\ H8=2_P"_[4?\)[XM_P"A
MAU+_ +_M0!]N45\1_P#">^+?^AAU+_O^U'_">^+?^AAU+_O^U 'VY2'[PKXD
M_P"$]\6_]##J7_?]J/\ A/?%O_0PZE_W_:@#[<HKXC_X3WQ;_P!##J7_ '_:
MC_A/?%O_ $,.I?\ ?]J /MRBOB/_ (3WQ;_T,.I?]_VH_P"$]\6_]##J7_?]
MJ /MRBOB/_A/?%O_ $,.I?\ ?]J/^$]\6_\ 0PZE_P!_VH ^W**^(_\ A/?%
MO_0PZE_W_:C_ (3WQ;_T,.I?]_VH ^W**^(_^$]\6_\ 0PZE_P!_VH_X3WQ;
M_P!##J7_ '_:@#[<HKXC_P"$]\6_]##J7_?]J/\ A/?%O_0PZE_W_:@#[:7O
M]:=7Q'_PGOBW_H8=2_[_ +4?\)[XM_Z&'4O^_P"U 'VY17Q'_P )[XM_Z&'4
MO^_[4?\ ">^+?^AAU+_O^U 'VY17Q'_PGOBW_H8=2_[_ +4?\)[XM_Z&'4O^
M_P"U 'VY17Q'_P )[XM_Z&'4O^_[4?\ ">^+?^AAU+_O^U 'VY17Q'_PGOBW
M_H8=2_[_ +4?\)[XM_Z&'4O^_P"U 'VQ)+'#&9)75$'5F. *DKX=O/&'B34+
M22UO-;OI[>08>.28E6'7D5WOPQ\>?$".]CT[2;:?7+13AH)\D1C_ *Z'[OXF
M@#ZC;I5.R_Y"&I?]=4_]%K4]N\TEK$]Q"(9BH+QA]X4^F>]067_(0U+_ *ZI
M_P"BUH O4444 %%%% !5#6O^0'>_]<&_E5^J&M?\@.]_ZX-_*@ BLK6ZMK9I
M[:*4K$N"Z!L<4[^R=._Y\+;U_P!4M2V?_'I!_P!<E_E5B@"E_9.G?\^%M_WZ
M7_"C^R=._P"?"V]?]4M7:* *7]D:=_SX6WK_ *I:/[)TX_\ +A;>O^J6KM%
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MH[Q-_P! O3?R?_&@#Z;HKYD_X:.\3?\ 0+TW\G_QH_X:.\3?] O3?R?_ !H
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MSZ=*W:* .8U+P38:KIMQI]Y=WLEK.Q9XPR+R>NW"_+GOBN6'P#\#$#]Q??\
M@2?\*]0/2D7[H^E 'F/_  H+P-_SPOO_  )/^%'_  H+P-_SPOO_  )/^%>G
MT4 >8?\ "@O W_/"^_\  D_X4?\ "@O W_/"^_\  D_X5Z?10!YA_P *"\#?
M\\+[_P "3_A1_P *"\#?\\+[_P "3_A7I]% 'F'_  H+P-_SPOO_  )/^%'_
M  H+P-_SPOO_  )/^%>GT4 >8?\ "@O W_/"^_\  D_X4?\ "@O W_/"^_\
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MJ/8"K%-7O]33J "BBB@ HHHH **** "BBB@ HHHH :W2J=E_R$-2_P"NJ?\
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M_P"@5<_]]+_C1_:-U_T"KG_OI?\ &@#2HK-_M&Z_Z!5S_P!]+_C1_:-U_P!
MJY_[Z7_&@#2I#U%9W]HW7_0*N?\ OI?\:/[1NLC_ (E5S_WTO^- &E16;_:-
MU_T"KG_OI?\ &N,\0_&3P_X6UB32M5M-1CNHU5F"1*PPPR.=U 'HM%>.:!^T
M'H-_J4MKJUM)8PF0B"Z W(4SQO'53^=>LV-_::G:)=6-S%<V[C*R0N&4_B*
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M*7=\DN]F_?1_PAN.6'][K2?V+JIQYCV4F?W<N]F/G1]@W'+#LW6NHHH Y?\
ML75N/,>RE)^23>S'SH^ROQRP[-UH_L35B1O>RDS^[DWLQ\Z+LK\<L.S=:ZBB
M@#EQHNK9&]K*3_EF^]F/FQ=E?CDCLW6K.EV&KZ79_9E:TE&]F#22N6Y.<$[>
M?K6_10!G%M8_YYV'_?Q__B:16UC:/W=A_P!_'_\ B:TCTI%^Z/I0!0W:S_SS
ML/\ OX__ ,31NUG_ )YV'_?Q_P#XFM"B@#/W:S_SSL/^_C__ !-&[6?^>=A_
MW\?_ .)K0HH S]VL_P#/.P_[^/\ _$T;M9_YYV'_ '\?_P")K0HH S]VL_\
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M]LZ9_P!!"V_[^K1_;.F?]!"V_P"_JT 7J0]15+^V=,_Z"%M_W]6D.L:9D?\
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M&W^%']I6O_0/O?\ P#;_  K5HH RO[2M?^@?>_\ @&W^%']I6O\ T#[W_P
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MOL[^Q-)_Z!=E_P" Z?X4?V)I/_0+LO\ P'3_  H ^,?^$Z\7?]#)JW_@4_\
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M9#?]!34/^_J__$T .\C5_P#G^M/_  &;_P"+H\C5_P#G^M/_  &;_P"+IO\
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MV$W_ $%]4_[_ (_^)H UJ*R?[";_ *"^J?\ ?\?_ !-']A-_T%]4_P"_X_\
MB: -:D/45E?V$W_07U3_ +_C_P")J%]"G-S$5UG4Q$%;>OG#)/&/X?K0!N45
MD_V$W_07U3_O^/\ XFC^PF_Z"^J?]_Q_\30!K45D_P!A-_T%]4_[_C_XFC^P
MF_Z"^J?]_P ?_$T :U%9/]A-_P!!?5/^_P"/_B:/[";_ *"^J?\ ?\?_ !-
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M,\,HP"*TZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
